Genentech, a member of the Roche group, announced that a third Phase III trial of Avastin in ovarian cancer met its endpoint of improvement in progression free survivial.
See the company’s release here
Genentech, a member of the Roche group, announced that a third Phase III trial of Avastin in ovarian cancer met its endpoint of improvement in progression free survivial.
See the company’s release here